PET scan to monitor immunotherapy response in solid tumors
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial uses a special scan (PET/CT) with an imaging agent that targets a protein called Granzyme B, which is produced by active immune cells. The scan helps doctors see how well immunotherapy is working in your tumor. You may join if you are about to start immunotherapy for a solid tumor and have not had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 90 years old.
- You must have been diagnosed with a solid tumor cancer, like lung, colon, or breast cancer.
- You must not have received any cancer treatment yet (treatment-naive).
- Your doctor must plan to start you on immunotherapy soon.
- You must not be pregnant or breastfeeding.
- You must be able to lie still for a PET/CT scan and have no allergies to the imaging agent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that may help doctors see tumors more clearly during a PET scan. It could help diagnose cancer or check if it has returned after treatment.
This study tests a new PET scan tracer that aims to highlight cancer cells more clearly. If you join, you'll receive one injection of the tracer and then have a PET/CT scan to help your doctor see whether you have cancer or where it is.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
This trial uses a special PET/CT scan (called 18F-grazy-02) to look at a protein in your body that may show how well your immune system is fighting the cancer. It is for people with non-small cell lung cancer or melanoma to help their doctors monitor the effects of immunotherapy.
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.